The Impact Of Acetyl-L-Carnitine In Modulating Viability And Inflammatory Cytokines In ACHN Renal Adenocarcinoma Cells

Abstract

Acetyl-L-Carnitine (ALCAR) is recognized for its roles in energy metabolism, neuroprotection, and modulation of inflammatory responses. The effects of ALCAR on cancer biology remain an emerging area of interest. This study investigates the impact of ALCAR on the ACHN renal adenocarcinoma cell line, focusing on cell viability and inflammatory cytokine regulation. ACHN cells were treated with ALCAR (0–2 µM) for 24 and 72 hours. ACHN cell viability was assessed via MTT test to determine the IC50. The levels of the pro-inflammatory cytokines IL-6, IL-1β, and TNF-α were quantified using ELISA.

The results demonstrated that ALCAR significantly decreased ACHN cell viability in a time- and dose-dependent manner, resulting in IC₅₀ values of 51.38 and 45.32 µM/mL at 24 and 72 hours, respectively. ALCAR also up regulated IL-1β and TNF-α levels significantly, while IL-6 levels showed no significant change.

In conclusion, the observed reduction in cancer cell survival highlights ALCAR's potential as a therapeutic agent, particularly in renal cell carcinoma. However, further research is required to elucidate the underlying mechanisms and optimize its application in targeted cancer therapies.